SAGE Therapeutics Inc. (SAGE) Is Suring On Phase 3 Study Results

SAGE Therapeutics Inc. (SAGE) announced Thursday morning that it met its primary endpoint in both of its Phase 3 studies of brexanolone in patients with severe postpartum depression.

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>